Evidence map›Paper›PMID 41378289›Full record

ArticleFrontiers in oncology2025

Multiline treatment of primary cutaneous adenoid cystic carcinoma with multiple metastases: a case report and literature review.

Xiaotao Geng, Daqing Sun, Huimin Sun, Chunyan Zhang, Jianwen Li, Furong Hao, Xiaolong Chang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiaotao GengDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Daqing SunDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Huimin SunDepartment of Pathology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Chunyan ZhangRadiation Oncology, Anqiu People's Hospital, Weifang, China.
Jianwen LiDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Furong HaoDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.
Xiaolong ChangDepartment of Radiation Oncology, Weifang People's Hospital, Shandong Second Medical University, Weifang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Primary cutaneous adenoid cystic carcinoma (PCACC) is an extremely rare malignancy, typically presenting as a slow-growing, painless cutaneous mass with a relatively favorable prognosis compared to adenoid cystic carcinomas (ACC) of salivary gland origin. Metastatic PCACC is uncommon, with stage IV disease accounting for approximately 4% of reported cases. Due to its rarity, clinical understanding of the disease course and optimal management strategies remains limited. Case presentation: We report the case of a 57-year-old male who presented with a painful ulcerated mass on the left ankle. Magnetic resonance imaging (MRI) revealed a subcutaneous lesion, and histopathological examination following surgical excision confirmed the diagnosis of ACC. Immunohistochemistry was consistent with ACC, and a PET-CT scan excluded regional or distant disease, supporting the diagnosis of PCACC. The patient subsequently underwent adjuvant radiotherapy. However, within eight months, follow-up imaging revealed pulmonary and osseous metastases. A biopsy confirmed metastatic ACC consistent with the primary lesion. The patient was treated sequentially with three lines of systemic therapy, including chemotherapy, immunotherapy, and targeted therapy, along with palliative radiotherapy. Despite temporary disease stabilization, the malignancy progressed rapidly, with new pulmonary, intracranial, and extensive skeletal metastases. The patient eventually discontinued treatment and was lost to follow-up. Conclusion: This case highlights an unusually aggressive clinical course of PCACC with rapid progression to widespread metastatic disease shortly after definitive local treatment. Given the rarity of metastatic PCACC, this report contributes valuable insight into its natural history, diagnostic approach, and therapeutic challenges. It underscores the need for heightened clinical awareness and further research into effective systemic treatment strategies for advanced PCACC.

Indexed as

chemotherapyimmunotherapyPD-1 inhibitorprimary cutaneous adenoid cystic carcinomaradiotherapysurgery

Identifiers

PMID41378289
PMCPMC12685681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.